

25<sup>th</sup> February, 2021

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 500302, 912460

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PEL

Dear Sir / Madam,

**Sub: Intimation of Virtual Conference/ Meeting with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

Pursuant to Regulation 30(6) of the Listing Regulations, please find enclosed herewith the details of the Piramal Pharma Day Virtual Conference/ Meeting with Investors/ Analysts.

Kindly take the above on record.

Thanking you,

Yours truly,  
For **Piramal Enterprises Limited**

**Bipin Singh**  
**Company Secretary**

Encl.: a/a

# PIRAMAL PHARMA DAY

**Speakers:**

- Ajay Piramal, Chairman, Piramal Group
- Nandini Piramal, Executive Director, Piramal Enterprises Ltd
- Peter DeYoung, CEO, Piramal Global Pharma, Piramal Pharma Ltd
- John Fowler, Chief Operating Officer, CDMO
- Stuart Needleman, Chief Commercial Officer & Chief Patient Centricity Officer, CDMO
- Michael Logerfo, President and Chief Operating Officer, Complex Hospital Generics
- Nitish Bajaj, CEO, India Consumer Products
- Vivek Valsaraj, President & CFO, Piramal Enterprises Ltd
- Hitesh Dhaddha, Chief Investor Relations Officer, Piramal Enterprises Ltd

**Agenda:****Hour 1:** Introduction to Piramal Pharma

- Evolution of the Pharma Business
- Overview and key highlights of Piramal Pharma Ltd
- Organic and Inorganic Expansion

**Hour 2:** Update on Business Verticals

- CDMO
- Complex Hospital Generics
- India Consumer Products
- Ophthalmology Branded Products
- Future Strategy

**Followed by Q&A Session****About Company:**

Piramal Enterprises Ltd (PEL), a publicly listed company in India, has diversified business interests in Financial Services and Pharmaceuticals, with market capitalization of over USD 5 billion. Piramal Pharma Ltd (PPL), a subsidiary of Piramal Enterprises Ltd, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries. PPL includes an integrated Contract Development and Manufacturing (CDMO) business, Complex Hospital Generics business, and India Consumer Products business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. During FY2021, PPL raised strategic growth investment for its 20% stake from The Carlyle Group.

**Friday,****Feb 26, 2021****4:30 p.m. – 7:00 p.m.**  
(India Time)

Registration Link:

[Please click to register](#)

\*\*\* The meeting will be conducted via ZOOM and in English only. \*\*\*

\*\*\* The session will be recorded. \*\*\*

**Event Coordinator:****Mayank Kumar****Anupam Jain**[investor.relations@piramal.com](mailto:investor.relations@piramal.com)